MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds

Merck and Moderna's personalized mRNA vaccine for melanoma reduced relapse risk by 42% in a phase 3 trial, with 82.2% of vaccinated patients relapse-free after 2 years. The vaccine targets neoantigens unique to each patient's tumor, but concerns include high costs and potential limitations compared to existing immunotherapies, according to SCIENCE.

JP Morgan kept its Overweight rating on Merck & Co and increased its price target to $175 from $165, suggesting a 17% upside from the Oct 30 close. Recent analyst targets range from $140 to $180.

Merck (MRK) shares rose 2.6% to $150.13 after JPMorgan raised its price target to $175. Q3 sales hit $18.085B, with Keytruda and Qlex generating $8.6B (9.7% from Qlex). Keytruda accounted for 48% of total sales. MRK has a P/E ratio of 120 and a GF Score of 81/100.

Moderna and Merck's mRNA cancer vaccine, intismeran, reduced melanoma recurrence risk by 42% in a study. The personalized vaccine, combined with Keytruda, showed 82% of patients cancer-free after two years. The companies are discussing regulatory approval. Moderna shares dropped 18% on the detailed results.

Moderna and Merck presented data on their cancer vaccine at ESMO, meeting expectations but causing a double-digit share price drop due to investor uncertainty. Tango Therapeutics also shared positive trial results but saw its shares fall, possibly due to lower-than-hoped response rates and workforce reduction plans.

An article outlines a $250,000 investment in four healthcare stocks—UnitedHealth (UNH), Merck (MRK), AbbVie (ABBV), and Pfizer (PFE)—yielding about $8,000 annually in dividends. Each company's dividend yield, shares purchased, and annual income are detailed, with Pfizer offering the highest yield at 5.74%. The article also discusses dividend safety and company-specific risks.